Ther Adv Med Oncol

期刊全称Ther Adv Med Oncol
注：上述信息均来源于网络，仅供查考，如有遗漏或信息错误，欢迎 向我反馈。

期刊相关文献 (9)

The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

靶向ROR1的抗体药物偶联物NBE-002在高级别浆液性卵巢癌临床前模型中具有活性。

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/17588359251332471
Dongli Liu ，Cassandra J Vandenberg ，Patrizia Sini ，Lorenz Waldmeier ，Rosa Baumgartinger ，Laura Pisarsky ，Georg Petroczi ，Gayanie Ratnayake ，Clare L Scott ，Caroline E Ford
发表日期：2025
全文求助 收藏

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

患者和患者来源的临床前模型中奥希替尼耐药性的分子图谱

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/17588359221079125.
Sun Min Lim ,San-Duk Yang ,Sangbin Lim ,Seong Gu Heo ,Stetson Daniel ,Aleksandra Markovets ,Rafati Minoo ,Kyoung-Ho Pyo ,Mi Ran Yun ,Min Hee Hong ,Hye Ryun Kim ,Byoung Chul Cho
发表日期：2022
全文求助 收藏

Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine

甲氨蝶呤通过激活NLRP3炎症小体增强肿瘤抗原呈递和负载肿瘤抗原的树突状细胞的成熟：一种基于树突状细胞的癌症疫苗策略

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/1758835920987056
Gao-Na Shi ，Min Hu ，Chengjuan Chen ，Junmin Fu ，Shuai Shao ，Yu Zhou ，Lei Wu ，Tiantai Zhang
发表日期：2021
全文求助 收藏

Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer

利用全面的分子谱分析预测胰腺癌的临床结果

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/17588359211038478
Jung Yong Hong ,Hee Jin Cho ,Seung Tae Kim ,Young Suk Park ,Sang Hyun Shin ,In Woong Han ,Jeeyun Lee ,Jin Seok Heo ,Joon Oh Park
发表日期：2021
全文求助 收藏

NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer

NDUFA4L2促进HER2阳性乳腺癌对曲妥珠单抗的耐药性

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/17588359211027836
Yuan Yuan ,Huanyao Gao ,Yongxian Zhuang ,Lixuan Wei ,Jia Yu ,Zhe Zhang ,Lili Zhang ,Liewei Wang
发表日期：2021
全文求助 收藏

Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients

开发和验证一种与缺氧相关的基因特征，用于预测早期肺腺癌患者的总生存期

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/1758835920937904.
Jing Sun ,Tianyu Zhao ,Di Zhao ,Xin Qi ,Xuanwen Bao ,Run Shi ,Chuan Su
发表日期：2020
全文求助 收藏

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer

抑制Wnt/β-catenin通路可增强卵巢癌的抗肿瘤免疫力

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/1758835920913798
David W Doo ，Selene Meza-Perez ，Angelina I Londoño ，Whitney N Goldsberry ，Ashwini A Katre ，Jonathan D Boone ，Dylana J Moore ，Cindy T Hudson ，Ilaria Betella ，Tyler R McCaw ，Abhishek Gangrade ，Riyue Bao ，Jason J Luke ，Eddy S Yang ，Michael J Birrer ，Dmytro Starenki ，Sara J Cooper ，Donald J Buchsbaum ，Lyse A Norian ，Troy D Randall ，Rebecca C Arend
发表日期：2020
全文求助 收藏

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release

靶向糖蛋白聚糖-3的裂解嵌合抗原受体修饰的T细胞可抑制肝细胞癌的生长并减少细胞因子释放

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/1758835920910347
Xuan Liu ，Jianyun Wen ，Honglei Yi ，Xiaorui Hou ，Yue Yin ，Guofu Ye ，Xuedong Wu ，Xiaotao Jiang
发表日期：2020
全文求助 收藏

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole

KW-2450（一种双重IGF-1R/IR酪氨酸激酶抑制剂）联合拉帕替尼和来曲唑的临床前和I期临床研究

期刊:Ther Adv Med Oncol
影响因子:4.300
doi:10.1177/1758835918786858.
Hiroshi Umehara ,Yoshimi Maekawa ,Fumito Koizumi ,Makiko Shimizu ,Toshio Ota ,Tamer M Fouad ,Jie Willey ,Hidekuni Kaito ,Norihiko Shiraishi ,Daisuke Nakashima ,Shiro Akinaga ,Naoto T Ueno
发表日期：2018
全文求助 收藏
  • 1